CELLULAR ENGINEERING TO TREAT/PREVENT DISEASES OF AGING
Project Number3R37AG005628-15S1
Former Number5R01AG003592-03
Contact PI/Project LeaderGOOD, ROBERT A
Awardee OrganizationUNIVERSITY OF SOUTH FLORIDA
Description
Abstract Text
We propose to continue long-term efforts to perfect bone marrow
transplantation (BMT) as a means to prevent or treat many different
diseases. This series of systematic experimental investigations will
explore further the usefulness of bone marrow or fetal liver cell
transplantation and ultimately stem cell transplantation as an experimental
approach to analysis, prevention or treatment of a number of diseases and
disorders not yet effectively treated. First we will explore BMT as an
approach to prevention or to causation of senility in mice. We will try to
prevent senility associated disease or disorders, including amyloid
deposition and arthritis or arthroses, in senility accelerated mice
[SAM(P)] mice. Alternatively, congenic or allogeneic BMT or congenic or
allogeneic neonatal liver transplantation will be tested as a means of
introducing from SAM(P) into the congenic resistant SAM(R) mice the
senility accelerating propensity. Similarly, BMT will be tested as a means
of causing, preventing or treating senility-associated changes and
amyloidosis when BMT donors share the major histocompatibility complex
(MHC) but are allogeneic to the SAM(P) mice, e.g. CBA/H or C3H/He.
Alternatively, we will attempt to use donors that differ from SAM(P) at
MHC, e.g. C57B1/6. BMT will also be tested as a means of preventing or
treating two new models of non-inflammatory coronary vascular diseases or
atherosclerosis in inbred mice. We will compare the immunological
consequences of long-term BMT induced chimeric state where BMT have either
been performed from autoimmune-resistant donors to mice of autoimmune-prone
strains or to mice of autoimmune-resistant strains. We will also ascertain
whether it is possible to treat effectively by BMT advanced, putatively
irreversible kidney disease associated with autoimmunity states.
Experiments will attempt to employ BMT from MHC-matched, MHC-mismatched or
haploidentical donors to treat effectively advanced kidney disease by
complete correction by BMT of the autoimmunity and immunologic
dysregulation that led to the kidney disease in the first place. Finally,
we will initiate experiments to evaluate the potential of stem cell
preparations to reconstruct the entire hematopoietic and lymphoid systems
and immunologic functions as an approach to correcting the genetically
determined propensity to develop autoimmunities nad other diseases
associated with aging and to analyze and influence the abnormal
accumulations of Ly1+ B lymphocytes that occur in these autoimmune states.
No Sub Projects information available for 3R37AG005628-15S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R37AG005628-15S1
Patents
No Patents information available for 3R37AG005628-15S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R37AG005628-15S1
Clinical Studies
No Clinical Studies information available for 3R37AG005628-15S1
News and More
Related News Releases
No news release information available for 3R37AG005628-15S1
History
No Historical information available for 3R37AG005628-15S1
Similar Projects
No Similar Projects information available for 3R37AG005628-15S1